Trump threatens $200bn in additional tariffs on Chinese products
US President Donald Trump has threatened to impose a 10% tariff on
an additional $200bn of Chinese imports. This move would broaden the US
administrations’ efforts to expand the previous list of Chinese goods on which
an import tariff was imposed. The US administration said that these moves were
necessary to address the unfair benefits to China from its trade balance with
the US.
Asian markets fell sharply on this announcement with the Shanghai
Composite and Hang Seng Index currently down 4.5% and 3%, respectively. Other
major Asian indices are also trading sharply lower, with the Nikkei 225, and
Kospi down 1.7 and 1.6%, respectively. In India, the Nifty is trading 0.7%
lower on weak global cues.
Dr Reddy's launch Levetiracetam injection in US
Dr Reddy Lab Dr Reddy's Laboratories has announced that it has
launched Levetiracetam in Sodium Chloride Injection in various strengths. This
is a therapeutic equivalent generic version of HQ Specialty Pharma Corp's
Levetiracetam in Sodium Chloride Injection.
The Levetiracetam in Sodium Chloride Injection brand and generic
had US sales of ~$37mn for the most recent 12 months’ period ending in April
2018 according to IMS Health.
USFDA approves supplemental ANDA from Glenmark’s North Carolina
facility
Global pharmaceutical company, Glenmark Pharmaceuticals has
announced that the USFDA provided its first supplemental Abbreviated New Drug
Application (sANDA) approval for the company’s manufacturing facility in
Monroe, North Carolina.
The approval covers Atovaquone and Proguanil Hydrochloride
Tablets, 250mg/100mg and 62.5mg/25mg, a generic version of GlaxoSmithKline’s
Malarone® (atovaquone and proguanil hydrochloride) Tablets1.
Strides Shasun gets final USFDA approval to gNizoral
Stride Sasun Strides Shasun has announced that it has received
final USFDA approval for Ketoconazole Tablets USP, 200 mg. This is a generic
version Janssen Pharma’s Nizoral Tablets, 200 mg.
Company has said that Ketoconazole Tablet is part of the niche and
small volume product portfolio with limited competition in the US market. As
per IQVIA MAT April 2018 data, the US market for Ketoconazole Tablets was
approximately $7mn.
There are three approved generic products as per the USFDA website
Mylan, Taro and Teva. As per Bloomberg, ~85% market share is with Taro.
ICICI Prudential Life Insurance appoints N.S. Kannan as new MD
& CEO
The Board of ICICI Prudential Life Insurance Company has appointed
Mr. N.S. Kannan as the Managing Director & CEO of ICICI Prudential Life
Insurance Company for a period of five years, effective from June 19, 2018,
subject to regulatory and other approvals. Kannan takes over from Sandeep
Bakhshi who has been appointed as Whole-time Director and Chief Operating
Officer of ICICI Bank, subject to necessary approvals.
Kannan has been an Executive Director at ICICI Bank since May 01,
2009. His responsibilities included Finance, Treasury, Corporate Legal,
Operations, Secretarial, Corporate Communications, Corporate Branding,
Infrastructure Management and the Strategic Solutions Group. Prior to this, he
was an Executive Director on the Board of ICICI Prudential Life Insurance
Company. He joined ICICI Ltd. in 1991.
for more update you can contact us :
